158 related articles for article (PubMed ID: 17712824)
21. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
[TBL] [Abstract][Full Text] [Related]
22. The enzymatic inactivation of the fatty acid amide class of signaling lipids.
Cravatt BF; Lichtman AH
Chem Phys Lipids; 2002 Dec; 121(1-2):135-48. PubMed ID: 12505696
[TBL] [Abstract][Full Text] [Related]
23. Elucidation of fatty acid amide hydrolase inhibition by potent alpha-ketoheterocycle derivatives from Monte Carlo simulations.
Guimarães CR; Boger DL; Jorgensen WL
J Am Chem Soc; 2005 Dec; 127(49):17377-84. PubMed ID: 16332087
[TBL] [Abstract][Full Text] [Related]
24. Binding mode of new (thio)hydantoin inhibitors of fatty acid amide hydrolase: comparison with two original compounds, OL-92 and JP104.
Michaux C; Muccioli GG; Lambert DM; Wouters J
Bioorg Med Chem Lett; 2006 Sep; 16(18):4772-6. PubMed ID: 16844375
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase by follicle-stimulating hormone.
Grimaldi P; Rossi G; Catanzaro G; Maccarrone M
Vitam Horm; 2009; 81():231-61. PubMed ID: 19647115
[TBL] [Abstract][Full Text] [Related]
26. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
Hart T; Macias AT; Benwell K; Brooks T; D'Alessandro J; Dokurno P; Francis G; Gibbons B; Haymes T; Kennett G; Lightowler S; Mansell H; Matassova N; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Walls S; Wong M; Roughley S
Bioorg Med Chem Lett; 2009 Aug; 19(15):4241-4. PubMed ID: 19515560
[TBL] [Abstract][Full Text] [Related]
27. The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women.
Monteleone P; Tortorella A; Martiadis V; Di Filippo C; Canestrelli B; Maj M
Psychoneuroendocrinology; 2008 May; 33(4):546-50. PubMed ID: 18295974
[TBL] [Abstract][Full Text] [Related]
28. A second N-acylethanolamine hydrolase in mammalian tissues.
Ueda N; Tsuboi K; Lambert DM
Neuropharmacology; 2005 Jun; 48(8):1079-85. PubMed ID: 15910884
[TBL] [Abstract][Full Text] [Related]
29. Endocannabinoid hydrolases.
Ueda N
Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():521-34. PubMed ID: 12432941
[TBL] [Abstract][Full Text] [Related]
30. The expression of receptors for endocannabinoids in human and rodent skeletal muscle.
Cavuoto P; McAinch AJ; Hatzinikolas G; Janovská A; Game P; Wittert GA
Biochem Biophys Res Commun; 2007 Dec; 364(1):105-10. PubMed ID: 17935697
[TBL] [Abstract][Full Text] [Related]
31. Fatty acid amide hydrolase controls mouse intestinal motility in vivo.
Capasso R; Matias I; Lutz B; Borrelli F; Capasso F; Marsicano G; Mascolo N; Petrosino S; Monory K; Valenti M; Di Marzo V; Izzo AA
Gastroenterology; 2005 Sep; 129(3):941-51. PubMed ID: 16143133
[TBL] [Abstract][Full Text] [Related]
32. A MBP-FAAH fusion protein as a tool to produce human and rat fatty acid amide hydrolase: expression and pharmacological comparison.
Labar G; Vliet FV; Wouters J; Lambert DM
Amino Acids; 2008 Jan; 34(1):127-33. PubMed ID: 17476568
[TBL] [Abstract][Full Text] [Related]
33. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields.
Myllymäki MJ; Käsnänen H; Kataja AO; Lahtela-Kakkonen M; Saario SM; Poso A; Koskinen AM
Eur J Med Chem; 2009 Oct; 44(10):4179-91. PubMed ID: 19539407
[TBL] [Abstract][Full Text] [Related]
34. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid amide hydrolase in brain ventricular epithelium: mutually exclusive patterns of expression in mouse and rat.
Egertová M; Michael GJ; Cravatt BF; Elphick MR
J Chem Neuroanat; 2004 Nov; 28(3):171-81. PubMed ID: 15482903
[TBL] [Abstract][Full Text] [Related]
36. A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.
Kage KL; Richardson PL; Traphagen L; Severin J; Pereda-Lopez A; Lubben T; Davis-Taber R; Vos MH; Bartley D; Walter K; Harlan J; Solomon L; Warrior U; Holzman TF; Faltynek C; Surowy CS; Scott VE
J Neurosci Methods; 2007 Mar; 161(1):47-54. PubMed ID: 17083980
[TBL] [Abstract][Full Text] [Related]
37. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
Gustin DJ; Ma Z; Min X; Li Y; Hedberg C; Guimaraes C; Porter AC; Lindstrom M; Lester-Zeiner D; Xu G; Carlson TJ; Xiao S; Meleza C; Connors R; Wang Z; Kayser F
Bioorg Med Chem Lett; 2011 Apr; 21(8):2492-6. PubMed ID: 21392988
[TBL] [Abstract][Full Text] [Related]
38. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas.
Rubio M; de Miguel R; Fernández-Ruiz J; Gutiérrez-López D; Carai MA; Ramos JA
Drug Alcohol Depend; 2009 Jan; 99(1-3):354-8. PubMed ID: 18922654
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
Tarzia G; Duranti A; Gatti G; Piersanti G; Tontini A; Rivara S; Lodola A; Plazzi PV; Mor M; Kathuria S; Piomelli D
ChemMedChem; 2006 Jan; 1(1):130-9. PubMed ID: 16892344
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
Wang X; Sarris K; Kage K; Zhang D; Brown SP; Kolasa T; Surowy C; El Kouhen OF; Muchmore SW; Brioni JD; Stewart AO
J Med Chem; 2009 Jan; 52(1):170-80. PubMed ID: 19072118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
